Status:
ENROLLING_BY_INVITATION
COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO
Lead Sponsor:
Dr ayesha wahid
Conditions:
Vitiligo - Macular Depigmentation
Tacrolimus
Eligibility:
All Genders
15-70 years
Phase:
EARLY_PHASE1
Brief Summary
Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be as...
Detailed Description
Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and V...
Eligibility Criteria
Inclusion
- \- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months
Exclusion
- • Pregnant or lactating female patients.
- Skin malignancy or any other malignant skin condition.
- Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
- Prior history of allergy to tacrolimus or calcipotriol.
- Other form of treatment for vitiligo within at least 1 month.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06880042
Start Date
May 1 2025
End Date
August 30 2025
Last Update
June 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lahore general.hospital
Lahore, Punjab Province, Pakistan